No new approvals, withdrawals or safety communications affecting oncology today.
The trial most likely to reach a regulator next is EMERALD-3, which randomised 760 participants with embolisation-eligible hepatocellular carcinoma across three arms: durvalumab and tremelimumab with lenvatinib plus TACE, the same immunotherapy pair plus TACE, or TACE alone.
Median progression-free survival was 13.0 months for the triple combination against 9.8 for TACE alone, a hazard ratio of 0.70. Overall survival at a median 24.6 months was 39.5 against 34.7 months, hazard ratio 0.84 with an interval from 0.65 to 1.09 — not significant.
The safety numbers deserve equal billing. Serious adverse events occurred in 64% of the triple-combination arm, 51% with immunotherapy plus TACE, and 23% with TACE alone. Treatment-related deaths were seven of 287 with the triple combination — two myocarditis, and one each of hepatic failure, haemophagocytic lymphohistiocytosis, septic shock and cardiac failure — against none in the immunotherapy plus TACE arm and two of 290 with TACE alone.
A 3.2-month progression-free survival gain against a near-tripling of serious adverse events and 2% treatment-related mortality is the kind of trade a licence decision has to weigh explicitly.
- No new approvals, recalls or safety communications for oncology today
- Progression-free survival improved; overall survival interval still includes no effect
- Serious adverse events 64% against 23% for TACE alone
- Seven treatment-related deaths in the triple-combination arm, none in the doublet
- The immunotherapy-plus-TACE arm shows a similar PFS gain with far fewer serious events
The statistics, in plain English
Note the third arm. Immunotherapy plus TACE without lenvatinib achieved a similar progression-free survival hazard ratio (0.71) with serious adverse events at 51% rather than 64% and no treatment-related deaths. A three-arm trial lets you ask what each component contributes; here the comparison suggests lenvatinib adds most of the toxicity and little of the benefit.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free